Corvus Pharmaceuticals, Inc.

1.88 USD
+0.10 (+5.62%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Corvus Pharmaceuticals, Inc. stock is down -8.74% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 June’s closed higher than May.

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.